FunPep Company Limited Logo

FunPep Company Limited

Develops therapeutic solutions derived from functional peptides.

4881 | T

Overview

Corporate Details

ISIN(s):
JP3802640007
LEI:
Country:
Japan
Address:
茨木市彩都あさぎ七丁目7−15

Description

FunPep Company Limited is a research and development firm specializing in therapeutic solutions derived from functional peptides. The company leverages the biological properties of peptides—short chains of amino acids—to develop a portfolio of products including pharmaceuticals, medical devices, and functional cosmetics. Its primary focus is on creating peptide-based medicines through two main platforms: functional peptides and antibody-inducing peptides. A key candidate from its functional peptide platform, SR-0379, is in late-stage clinical trials. The company is also advancing an allergy vaccine and developing next-generation formulation technologies for its antibody-inducing peptide platform.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 08:30
確認書
Japanese 8.4 KB
2025-08-14 08:30
半期報告書-第13期(2025/01/01-2025/12/31)
Japanese 278.9 KB
2025-04-01 08:30
臨時報告書
Japanese 23.2 KB
2025-03-28 08:16
確認書
Japanese 8.5 KB
2025-03-28 08:15
有価証券報告書-第12期(2024/01/01-2024/12/31)
Japanese 1.6 MB
2025-03-28 08:15
内部統制報告書-第12期(2024/01/01-2024/12/31)
Japanese 23.6 KB
2025-02-21 07:30
有価証券届出書(組込方式)
Japanese 447.3 KB
2024-08-08 09:01
確認書
Japanese 8.4 KB
2024-08-08 09:00
半期報告書-第12期(2024/01/01-2024/12/31)
Japanese 283.1 KB
2024-08-08 03:00
臨時報告書
Japanese 21.3 KB
2024-07-05 08:05
有価証券届出書(組込方式)
Japanese 391.3 KB
2024-05-13 08:00
確認書
Japanese 8.4 KB
2024-05-13 08:00
四半期報告書-第12期第1四半期(2024/01/01-2024/03/31)
Japanese 238.2 KB
2024-04-01 08:05
臨時報告書
Japanese 27.7 KB
2024-03-28 07:15
確認書
Japanese 8.5 KB

Automate Your Workflow. Get a real-time feed of all FunPep Company Limited filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for FunPep Company Limited

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for FunPep Company Limited via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.